Nilsine Partners LLC Acquires 473 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Nilsine Partners LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 10,665 shares of the medical research company’s stock after purchasing an additional 473 shares during the period. Nilsine Partners LLC’s holdings in Thermo Fisher Scientific were worth $5,548,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. International Assets Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 76,051.4% in the third quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company’s stock worth $876,152,000 after buying an additional 1,414,556 shares in the last quarter. FMR LLC boosted its stake in Thermo Fisher Scientific by 19.7% during the third quarter. FMR LLC now owns 7,877,459 shares of the medical research company’s stock valued at $4,872,761,000 after buying an additional 1,294,453 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Thermo Fisher Scientific during the third quarter worth about $254,412,000. Lindsell Train Ltd purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $211,858,000. Finally, Franklin Resources Inc. grew its holdings in shares of Thermo Fisher Scientific by 5.7% during the third quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company’s stock worth $2,935,377,000 after purchasing an additional 262,062 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $583.43 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm has a market cap of $223.16 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. The firm’s 50 day simple moving average is $533.60 and its 200-day simple moving average is $569.81. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific announced that its board has authorized a share repurchase program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Bank of America decreased their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Finally, Morgan Stanley decreased their target price on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 34,850 shares of company stock worth $19,123,197. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.